Pain during angiography: a randomized double-blind trial comparing ioxaglate and diatrizoate.
We performed a randomized, double-blind prospective study comparing pain experienced during peripheral and aortic angiography with two different contrast agents. Sixty patients, receiving a total of 107 injections, were randomized to receive either ioxaglate (Hexabrix) or sodium-meglumine diatrizoate (Renografin-76). Subjects scored the pain they experienced on a 10-point visual analog scale, and the physician also scored their discomfort on a five point scale. Hemodynamic parameters were monitored during the procedure in all patients, and subsequent hematology, serum chemistry, and urinalysis were performed in 19 of the 60 patients. There was a significant reduction in the degree of pain experienced by the Ioxaglate group compared to the reference group (p less than 0.001). The patients in the Hexabrix group had a mean pain score of 1.3 compared to the patients in the Renografin-76 group who had a mean pain score of 6.1. The two groups did not differ in their hemodynamic responses to the contrast agents, and no significant differences were noted in the subsequent laboratory measures.
D000328:Adult; D000368:Aged; D000792:Angiography / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003973:Diatrizoate / Q000009:adverse effects*; D003974:Diatrizoate Meglumine / Q000009:adverse effects*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007485:Ioxaglic Acid / Q000009:adverse effects*; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced*; D011897:Random Allocation
D004338:Drug Combinations; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D007485:Ioxaglic Acid